AbbVie is twirling onto the dance floor with Disco Pharmaceuticals, offering up to $2.5 billion to work with the German platform company on cancer-targeted bispecific discovery.
The option-to-license agreement includes a $40 million upfront fee, with the rest of the cash tied to potential milestone payments. The aim is to identify and potentially advance highly selective bispecific therapeutics.
The biotech's DiscoTech platform maps the proteins on the cancer cell membrane, called the surfaceome, to reveal potential targets for AND-gated bispecific antibodies.
“The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors,” Disco CEO Mark Manfredi, Ph.D., said in a Nov. 19 release. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology,” added Manfredi, who took on the top job in December 2025.
Disco was formed in 2022 as a spinout from work conducted at Switzerland’s ETH Zürich research university. Roman Thomas, a professor of translational genomics at Cologne University, was initially appointed Disco’s CEO, while Dieter Weinand, a former CEO of German pharma giant Bayer, is chairman of the board.
AbbVie has been taking an interest in Disco for a while, with the pharma's VC arm contributing to the biotech's 20 million euros seed financing in 2024. The funding came at a time when the industry was gung-ho on antibody-based programs but had trouble differentiating cell surface targets, meaning that Disco’s mapping platform presented a potential solution.
AbbVie is no stranger to the bispecific world and has a late-stage BCMA x CD3 T-cell engager that in September showed improved response rates and progression-free survival in patients with relapsed or refractory multiple myeloma. The pharma has also lined up other partners in the space, including RemeGen in a January deal worth up to $5.6 billion.
Meanwhile, Disco's other dance partners include Amgen, who agreed a similar deal earlier this year worth up to $618 million with an eye toward developing a target the biotech had identified prior to the engagement.